Information Provided By: 
Fly News Breaks for November 27, 2018
LOXO
Nov 27, 2018 | 05:20 EDT
Piper Jaffray analyst Tyler Van Buren says Vitrakvi was approved last night as expected with no surprises on the label. The analyst believes the value-based pricing model is reasonable at $32,800 per month, but only for patients who respond, and roughly in-line with current expectations for net pricing. He currently models worldwide Vitrakvi/LOXO-195 combined sales approaching $1B by the mid-to-late 2020s. Van Buren keeps an Overweight rating on Loxo Oncology with a $200 price target.
News For LOXO From the Last 2 Days
There are no results for your query LOXO
